Centessa Pharmaceuticals Announces Preclinical Data From In Vivo And In Witro Studies Of ORX750
Portfolio Pulse from Benzinga Newsdesk
Centessa Pharmaceuticals has announced preclinical data from in vivo and in vitro studies of ORX750. The data showed significant activity at low doses of ORX750 in highly predictive translational models of Narcolepsy Type 1 (NT1). ORX750 is advancing in IND-enabling studies, with clinical proof of concept data planned for 2024.
October 25, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Centessa Pharmaceuticals' preclinical data for ORX750 shows significant activity in Narcolepsy Type 1 models. This could potentially boost the company's stock as it indicates progress in their drug development.
The announcement of positive preclinical data is generally a positive signal for biotech companies as it indicates progress in drug development. This could potentially lead to increased investor confidence in Centessa Pharmaceuticals, thereby positively impacting the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100